AstraZeneca buys cell therapy biotech in up to $1bn deal
AstraZeneca has struck a deal to acquire biotechnology company EsoBiotec for up to $1bn, as the London-listed pharmaceutical ...
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...
pharmaphorum27d
AstraZeneca gets further approval for Tagrisso in Japan
AstraZeneca received approval from the Japanese regulator following a priority review of Tagrisso (osimertinib) as a first-line treatment of patients with positive non-small cell lung cancer ...
Reuters29d
AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
The FibroGen-AstraZeneca drug, marketed as Evrenzo, is currently approved in China, Europe, Japan, and over 40 other countries for the treatment of anemia in patients with chronic kidney disease.
FierceBiotech4d
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the ...
Pharmabiz2d
EU approves AstraZeneca’s Imfinzi as monotherapy to treat adults with limited-stage small cell lung cancer
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...